Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Epinephrine Auto-injectors in Healthy Subjects
NCT03282929Phase 1Completed
- Sponsor
- Bausch + Lomb
- Start
- Mar 2017
- Primary completion
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of epinephrine in anaphylaxis (5 arms), sponsored by Bausch + Lomb. Primary endpoints: Maximum Observed Drug Concentration at 14 days and Time to Maximum Drug Concentration at 14 days. Started Mar 2017; status: completed.
02
Drugs
epinephrine
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT03282929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03282929.